Insider trading activity at Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) recently drew attention following the sale of company stock by Chief Medical Officer David Soergel. On June 1, 2026, Mr. Soergel disposed of shares totaling 1,042 units. The transaction was executed at a price point of $495.74 per share, resulting in total proceeds of $516,561.
It is noteworthy that the stock’s current market trading value stands at $481.23, which is slightly below the sale price but remains considerably higher than the stock's 52-week low established at $268.69. Despite maintaining an impressive gross profit margin of 93%, Madrigal Pharmaceuticals reported being unprofitable over the most recent twelve-month period.
The disposal of shares was conducted in accordance with a Rule 10b5-1 trading plan, which Mr. Soergel had initially adopted on March 2, 2026. Following this specific transaction, his direct personal ownership stake in Madrigal Pharmaceuticals common stock amounts to 10,033 shares.
In related market analysis, the stock is currently viewed by InvestingPro as appearing undervalued at its existing price levels. The platform also makes additional insights available through its comprehensive Pro Research Report for deeper review.
The positive momentum surrounding Madrigal Pharmaceuticals is further underlined by recent corporate announcements and external analyst actions. In Q1 2026, the company released earnings that outperformed market expectations. Specifically, the reported earnings per share (EPS) was -$3.25, which surpassed the forecasted figure of -$4.19. This represented a positive surprise margin of 22.43%. Furthermore, the revenue generated reached $311.3 million, exceeding the anticipated revenue of $301.29 million.
Clinical development efforts are also progressing significantly. Madrigal Pharmaceuticals is slated to present multiple abstracts detailing its Rezdiffra development at the European Association for the Study of the Liver Congress 2026 in Barcelona. These upcoming presentations will encompass analyses derived from two key trials: Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1. The focus of these clinical reports will be on demonstrating improvements in lipid profiles and assessing risk scores associated with portal hypertension.
The positive market reception has been solidified by major financial institutions. Citizens reaffirmed a 'Market Outperform' rating for Madrigal Pharmaceuticals, maintaining a price target set at $737.00. This sustained confidence follows the release of new clinical data highlighting Rezdiffra’s benefits for liver health. Additionally, Truist Securities elevated its price target to $709 from a previous level of $640, while simultaneously issuing a Buy rating. These adjustments were made subsequent to a survey that indicated physician preference favoring Rezdiffra as a treatment modality for MASH-related liver conditions.
The combination of strong operational metrics and positive clinical data suggests growing interest and increasing confidence in Madrigal Pharmaceuticals’ ongoing research pipeline and overall market potential within the healthcare sector.